Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 3:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 247 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Male and Female Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function

NCT00674856
View directory record Official record
Conditions
Renal Failure
Interventions
naproxcinod
Drug
Lead sponsor
NicOx
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

NCT04935294
View directory record Official record
Conditions
Healthy, Renal Dysfunction
Interventions
Danicopan
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects

NCT02412449
View directory record Official record
Conditions
Healthy
Interventions
AKB-6548 tablet, reference formulation given in the fasted state, AKB-6548 tablet, test formulation given in the fasted state., AKB-6548 tablet, test formulation given in the fed state
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects

NCT03722823
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Tucatinib
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Tustin, California • Orlando, Florida • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cefadroxil 500 mg Capsules Under Fasting Conditions

NCT00834275
View directory record Official record
Conditions
Healthy
Interventions
Cefadroxil 500 mg Capsules, DURICEF® capsules 500 mg
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

NCT00928083
View directory record Official record
Conditions
Malaria Falciparum, Malaria Vivax, Healthy Volunteers
Interventions
OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion, OZ439 800mg aqueous dispersion, OZ439 100mg API capsules, OZ439 400mg API capsules, OZ439 1600mg aqueous dispersion, OZ439 800mg API capsules, OZ439 1200mg API capsules, Placebo, OZ439 200mg aqueous dispersion
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

NCT05918614
View directory record Official record
Conditions
Immune System Disorder (Healthy Volunteer)
Interventions
Belumosudil mesylate, Placebo
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection

NCT05203289
View directory record Official record
Conditions
Healthy
Interventions
BI 695501 - higher concentration, BI 695501 - lower concentration
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 14, 2026, 3:13 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

NCT00787618
View directory record Official record
Conditions
Renal Impairment
Interventions
50 mg Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional

Dexpramipexole Renal PK Study

NCT01424176
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Renal Insufficiency
Interventions
Dexpramipexole (dose 1), Dexpramipexole (dose 2)
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Orlando, Florida • Brooklyn Center, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

NCT01309438
View directory record Official record
Conditions
Healthy, Renal Insufficiency
Interventions
Rivaroxaban (normal renal function), Rivaroxaban (mild and moderate renal impairment), Erythromycin (normal renal function), Erythromycin (mild and moderate renal function)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
35 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
4
States / cities
Orlando, Florida • Minneapolis, Minnesota • Saint Paul, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.

NCT00812318
View directory record Official record
Conditions
HIV Infection, Infection, Human Immunodeficiency Virus
Interventions
GSK1265744 10 mg oral solution, GSK1265744 5 mg tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2012 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Fostamatinib in Subjects With Impaired Kidney Function

NCT01245790
View directory record Official record
Conditions
Rheumatoid Arthritis, Renal Impairment
Interventions
fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide

NCT01366365
View directory record Official record
Conditions
Healthy Adults
Interventions
methylnaltrexone, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

NCT01129414
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel, Placebo, Omeprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

NCT03325595
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AEF0117, Placebo
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects

NCT01171105
View directory record Official record
Conditions
Healthy
Interventions
AZD5213, Placebo to AZD5213
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects

NCT02157558
View directory record Official record
Conditions
Drug Interactions
Interventions
Fexofenadine, Telotristat etiprate
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 14, 2026, 3:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™

NCT03095391
View directory record Official record
Conditions
Kidney Diseases, Renal Insufficiency, Chronic, Acute Kidney Injury, Urologic Diseases, Renal Insufficiency
Interventions
VFI, Iohexol
Device
Lead sponsor
FAST BioMedical
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Birmingham, Alabama • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects

NCT00846196
View directory record Official record
Conditions
Osteoporosis
Interventions
risedronate DR (Phase III clinical supply), risedronate 35 mg DR (Commercial Tablet)
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 65 Years
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
6
States / cities
San Diego, California • Fort Myers, Florida • Miramar, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects

NCT03237988
View directory record Official record
Conditions
Healthy Subjects
Interventions
CPI-444 Capsules, CPI-444 Tablets
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function

NCT03192111
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteer
Interventions
Entinostat
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects

NCT05529849
View directory record Official record
Conditions
Cachexia
Interventions
TCMCB07, Placebo
Drug
Lead sponsor
Endevica Bio
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 14, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Effect of Food on the Pharmacokinetics of a Single JNJ-39823277 (TPI-1062) Dose in Healthy Participants

NCT02103985
View directory record Official record
Conditions
Healthy
Interventions
JNJ-39823277
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 14, 2026, 3:13 PM EDT